Copyright 2024 All rights reserved.
What We Do
By overcoming barriers that seemed impossible, we have established platform
technologies for development of pharmaceuticals that anyone can safely use regardless of time and place.
What We Do
Primal Immune System
Fetal Immune System in early pregnancy
Our immune system produces antibodies called immunoglobulins to protect us from external infections such as SARS-CoV-2. B cells that can produce immunoglobulins against external
infections are only found after 18 weeks of pregnancy, and the mother's antibodies are transmitted through the umbilical cord after 15 weeks of pregnancy. Then, how can the fetus before
that time be protected from external infections?
Fetal Self-Defense System
Caused by pregnancy-related hormones
We are the first to establish fetal self-defense mechanisms activated by pregnancy hormones. First, the "immune tolerance" mechanism
activated by the progesterone hormone induces the expression and secretion of HLA-G protein to protect the fetus from the mother's immune
cells. Second, it is a "primal immune system" mechanism activated by estrogen hormone, which induces the expression and secretion of natural
antibodies (NAbs) including IgM and IgP (IgG3 secreted from fetal stem cells in early pregnancy) to protect the fetus from external infection.
Primal Immune System
We found that the fetus possesses very complicated and sophisticated self-defense mechanisms (primal immune system) at the cellular level. (A) Extracellular defense mechanism by secretion of IgP (primal immunoglobulins) and complement proteins to eliminate external pathogens immediately by antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). (B) Defense mechanism at cell membranes to inhibit viral binding and entry into cells by interferon(IFN)-inducing proteins including IFITM1, LY6E, and HLA-G. (C) Intracellular defense mechanism to inhibit viral replication and transmission by activating anti-viral autophagy.
Development of IgP-containing EV therapeutics for prevention
and treatment of infectious diseases
Possible to protect us from
unexperienced antigens
including SARS-CoV-2
We found for the first time that the reason why the infection rate and fatality rate to SARS-CoV-2 increases with age is because primal immunity, which exists before innate immunity, gradually decreases with age. For this reason, the innate immune system, which should act as the immediate first line of defense until the adaptive immune system is activated during viral infection, is weakened, and as a result, the adaptive immune system is abnormally induced, and the infection rate and fatality rate increase with age. We developed the immune-tolerized Extracellular vesicles therapeutics containing various factors constituting the primal immune system that can strengthen the innate immune system, including primal immunoglobulin (IgP), complement proteins, and interferon-derived proteins that play an anti-viral effect. Through this, it is expected that prevention and treatment of all infectious diseases will be possible by immediately responding to any unexperienced antigens as well as already experienced antigens.
